2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2050

Are Patients Meeting the Updated Physical Activity Guidelines? Physical Activity Participation, Recommendation, and Preferences Among Adults with Rheumatic Diseases
Abstract Number: 494

Are There Gender Specific Differences in Patient Characteristics At Initiation of Biologic Treatment in Rheumatoid Arthritis?
Abstract Number: 1632

Arhalofenate Is a Novel Dual-Acting Agent with Uricosuric and Anti-Inflammatory Properties
Abstract Number: 702

Arterial Stiffness Is Increased in Systemic Sclerosis: A Cross-Sectional Comparison with Matched Controls
Abstract Number: 2573

Arthoplasty Rates Increased Among US Patients with Systemic Lupus Erythematosus: 1991-2005
Abstract Number: 2432

Arthritis Foundation’s Tai Chi Program for People with Arthritis: One Year Follow-up
Abstract Number: 2416

Arthritis-Attributable Interference in Routine Life Activities
Abstract Number: 12

Articular Cartilage Expresses the IL-15 Receptor Alpha-Chain and Responds to IL-15 with Increased Matrix Metalloproteinase Release
Abstract Number: 1922

Articular Involvement in Relapsing Polychondritis: A Case Series
Abstract Number: 2024

Articular Symptoms in Cryopyrin-Associated Periodic Syndrome: Retrospective French Study
Abstract Number: 2604

Ask a Doc – Rheumatologic Care Delivered Just in Time
Abstract Number: 2084

ASP015K: A Novel JAK Inhibitor Demonstrated Potent Efficacy in Adjuvant-Induced Arthritis Model in Rats
Abstract Number: 2369

Aspects of Innate Immunity in Behçet´s Disease: A Model of Autoinflammatory Disease?
Abstract Number: 2209

Assessing Active Inflammation in Sacroiliac Joints in Spondyloarthritis Patients: No Added Value of Gadolinium Compared to Short Tau Inversion Recovery Sequence
Abstract Number: 1528

Assessing Fatigue in Systemic Vasculitis From the Patient’s Perspective

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].